JP2014500722A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014500722A5 JP2014500722A5 JP2013538823A JP2013538823A JP2014500722A5 JP 2014500722 A5 JP2014500722 A5 JP 2014500722A5 JP 2013538823 A JP2013538823 A JP 2013538823A JP 2013538823 A JP2013538823 A JP 2013538823A JP 2014500722 A5 JP2014500722 A5 JP 2014500722A5
- Authority
- JP
- Japan
- Prior art keywords
- glucocerebrosidase
- mutant recombinant
- glucocerebrosidase protein
- recombinant
- protein according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102000004547 Glucosylceramidase Human genes 0.000 claims 16
- 108010017544 Glucosylceramidase Proteins 0.000 claims 16
- 230000003197 catalytic effect Effects 0.000 claims 3
- 230000007935 neutral effect Effects 0.000 claims 3
- 150000001413 amino acids Chemical class 0.000 claims 2
- 238000011534 incubation Methods 0.000 claims 2
- 230000035772 mutation Effects 0.000 claims 2
- 230000004962 physiological condition Effects 0.000 claims 2
- 208000015439 Lysosomal storage disease Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000000717 retained effect Effects 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US41133110P | 2010-11-08 | 2010-11-08 | |
| US61/411,331 | 2010-11-08 | ||
| US41218010P | 2010-11-10 | 2010-11-10 | |
| US61/412,180 | 2010-11-10 | ||
| PCT/US2011/059731 WO2012064709A2 (en) | 2010-11-08 | 2011-11-08 | Variant, recombinant beta-glucocerebrosidase proteins with increased stability and increased retained catalytic activity |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017000301A Division JP6457559B2 (ja) | 2010-11-08 | 2017-01-05 | 増加した安定性および増加した保持触媒活性を有する変異型組換えβ−グルコセレブロシダーゼタンパク質 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014500722A JP2014500722A (ja) | 2014-01-16 |
| JP2014500722A5 true JP2014500722A5 (cg-RX-API-DMAC10.html) | 2014-12-25 |
| JP6073796B2 JP6073796B2 (ja) | 2017-02-01 |
Family
ID=46051505
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013538823A Active JP6073796B2 (ja) | 2010-11-08 | 2011-11-08 | 増加した安定性および増加した保持触媒活性を有する変異型組換えβ−グルコセレブロシダーゼタンパク質 |
| JP2017000301A Active JP6457559B2 (ja) | 2010-11-08 | 2017-01-05 | 増加した安定性および増加した保持触媒活性を有する変異型組換えβ−グルコセレブロシダーゼタンパク質 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017000301A Active JP6457559B2 (ja) | 2010-11-08 | 2017-01-05 | 増加した安定性および増加した保持触媒活性を有する変異型組換えβ−グルコセレブロシダーゼタンパク質 |
Country Status (19)
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020157248A1 (en) * | 2019-02-01 | 2020-08-06 | Oxyrane Uk Ltd | Glucocerebrosidase polypeptides |
| CN113795575A (zh) | 2019-02-04 | 2021-12-14 | 自由行疗法有限公司 | 多核苷酸 |
| US20220325265A1 (en) | 2019-09-09 | 2022-10-13 | Hoffmann-La Roche Inc. | Glucocerebrosidase mutants |
| WO2021199039A1 (en) * | 2020-03-29 | 2021-10-07 | Yeda Research And Development Co. Ltd. | Variants of beta-glucocerebrosidase for use in treating gaucher disease |
| KR20230042513A (ko) * | 2020-07-29 | 2023-03-28 | 프리라인 테라퓨틱스 리미티드 | 폴리펩티드 |
| WO2023145814A1 (ja) * | 2022-01-31 | 2023-08-03 | 株式会社日本触媒 | 向上した酵素活性または向上した安定性を有する組換えグルコセレブロシダーゼタンパク質 |
| JPWO2023145813A1 (cg-RX-API-DMAC10.html) * | 2022-01-31 | 2023-08-03 | ||
| WO2023145812A1 (ja) * | 2022-01-31 | 2023-08-03 | 株式会社日本触媒 | グルコセレブロシダーゼ活性を有する糖鎖付加タンパク質 |
| WO2023198661A1 (en) | 2022-04-12 | 2023-10-19 | F. Hoffmann-La Roche Ag | Fusion proteins targeted to the central nervous system |
| CN121406674A (zh) * | 2022-10-08 | 2026-01-27 | 凌意(杭州)生物科技有限公司 | 用于治疗GCase缺乏相关疾病的多核苷酸 |
| AU2024394235A1 (en) * | 2023-12-08 | 2026-06-11 | Denali Therapeutics Inc. | Modified glucocerebrosidase polypeptides and methods of use thereof |
| TW202617982A (zh) * | 2024-06-24 | 2026-05-01 | 美商戴納立製藥公司 | 包含經修飾之葡萄糖腦苷脂酶多肽之融合蛋白及其方法 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH03503721A (ja) * | 1988-12-23 | 1991-08-22 | ジェンザイム コーポレイション | 酵素的に活性な組換えグルコセレブロシダーゼ |
| JP2893481B2 (ja) | 1988-12-23 | 1999-05-24 | ジェンザイム コーポレイション | 酵素的に活性な組換えグルコセレブロシダーゼ |
| US6524613B1 (en) | 1997-04-30 | 2003-02-25 | Regents Of The University Of Minnesota | Hepatocellular chimeraplasty |
| NZ500694A (en) | 1997-04-30 | 2001-09-28 | Univ Minnesota | Use of chimeric mutational vector (CMV), a macromolecule and a ligand for cell surface receptor adhesion molecule (clatherin) in gene therapy; the CMV vector derived from REC2 homologous pairing with Ustilago maydis |
| EP1027069B1 (en) * | 1997-10-29 | 2006-07-26 | Genzyme Corporation | Gene therapy for gaucher disease |
| IL141403A0 (en) | 1998-08-28 | 2002-03-10 | Univ Duke | Deleted adenoviruses and methods of making and administering the same |
| IL150314A0 (en) | 1999-12-30 | 2002-12-01 | Maxygen Aps | Improved lysosomal enzymes and lysosomal enzyme activators |
| US20020127219A1 (en) * | 1999-12-30 | 2002-09-12 | Okkels Jens Sigurd | Lysosomal enzymes and lysosomal enzyme activators |
| IL152110A0 (en) | 2000-04-06 | 2003-07-31 | Exegenics Inc | Expression system for efficiently producing clinically effective lysosomal enzymes (glucocerebrosidase) |
| AU2001267337A1 (en) * | 2000-06-30 | 2002-01-14 | Maxygen Aps | Peptide extended glycosylated polypeptides |
| US7855063B2 (en) * | 2003-04-16 | 2010-12-21 | Yeda Research And Development Co. Ltd. | Partially deglycosylated glucocerebrosidase polypeptide and crystals thereof |
| WO2005089047A2 (en) | 2004-03-18 | 2005-09-29 | Glycofi, Inc. | Glycosylated glucocerebrosidase expression in fungal hosts |
| AU2008245578A1 (en) * | 2007-04-26 | 2008-11-06 | Amicus Therapeutics, Inc. | Dosing regimens for the treatment of lysosomal storage diseases using pharmacological chaperones |
| KR101789000B1 (ko) * | 2007-05-22 | 2017-10-20 | 아미쿠스 세라퓨틱스, 인코포레이티드 | 이소파고민과 이의 유도체를 제조하는 새로운 방법 |
| US9150849B2 (en) | 2007-11-02 | 2015-10-06 | The Scripps Research Institute | Directed evolution using proteins comprising unnatural amino acids |
| EP2220218A4 (en) | 2007-11-02 | 2010-12-08 | Scripps Research Inst | GENETICALLY ENCODED BORONATE AMINO ACID |
-
2011
- 2011-11-08 US US13/884,126 patent/US8962564B2/en active Active
- 2011-11-08 PT PT118394287T patent/PT2638152T/pt unknown
- 2011-11-08 EP EP11839428.7A patent/EP2638152B1/en active Active
- 2011-11-08 BR BR112013011152A patent/BR112013011152A2/pt not_active Application Discontinuation
- 2011-11-08 WO PCT/US2011/059731 patent/WO2012064709A2/en not_active Ceased
- 2011-11-08 ES ES16178095T patent/ES2743825T3/es active Active
- 2011-11-08 PL PL11839428T patent/PL2638152T3/pl unknown
- 2011-11-08 LT LTEP11839428.7T patent/LT2638152T/lt unknown
- 2011-11-08 CN CN201510671991.0A patent/CN105296447A/zh active Pending
- 2011-11-08 KR KR1020137014671A patent/KR101901467B1/ko active Active
- 2011-11-08 SI SI201131025A patent/SI2638152T1/sl unknown
- 2011-11-08 CN CN201180064243.6A patent/CN103314105B/zh not_active Expired - Fee Related
- 2011-11-08 EP EP16178095.2A patent/EP3144386B1/en active Active
- 2011-11-08 DK DK11839428.7T patent/DK2638152T3/en active
- 2011-11-08 JP JP2013538823A patent/JP6073796B2/ja active Active
- 2011-11-08 RS RS20161010A patent/RS55405B1/sr unknown
- 2011-11-08 CA CA2817011A patent/CA2817011C/en active Active
- 2011-11-08 HU HUE11839428A patent/HUE030932T2/en unknown
- 2011-11-08 ES ES11839428.7T patent/ES2604490T3/es active Active
- 2011-11-08 HR HRP20161560TT patent/HRP20161560T1/hr unknown
-
2015
- 2015-02-02 US US14/611,495 patent/US9254313B2/en active Active
-
2016
- 2016-01-04 US US14/987,204 patent/US9566316B2/en active Active
- 2016-11-24 SM SM201600431T patent/SMT201600431B/it unknown
- 2016-11-29 CY CY20161101239T patent/CY1118843T1/el unknown
-
2017
- 2017-01-05 JP JP2017000301A patent/JP6457559B2/ja active Active
- 2017-02-13 US US15/430,682 patent/US9821038B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016505539A5 (cg-RX-API-DMAC10.html) | ||
| WO2012064709A3 (en) | Variant, recombinant beta-glucocerebrosidase proteins with increased stability and increased retained catalytic activity | |
| NL300874I2 (nl) | Elosulfase alfa | |
| MX2024010190A (es) | Inclusion del exon2 inducida por antisentido en alfa-glucosidasa acida. | |
| BR112012033197A2 (pt) | métodos e composições para liberação de cns de n-sulfatase de heparano. | |
| JP2013519365A5 (cg-RX-API-DMAC10.html) | ||
| EP4548972A3 (en) | (2s)-n-[(1s)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase i inhibitors | |
| JP2013520405A5 (cg-RX-API-DMAC10.html) | ||
| JP2012532596A5 (cg-RX-API-DMAC10.html) | ||
| CY1118934T1 (el) | Παρασκευη ενεργης ακρως φωσφορυλιωμενης ανθρωπινης ν-ακετυλογαλακτοζαμινης-6-σουλφατασης και χρησεις αυτης | |
| JP2010512795A5 (cg-RX-API-DMAC10.html) | ||
| MX2013001749A (es) | Composiciones y metodos para tratar enfermedades cardiovasculares. | |
| CY1116892T1 (el) | Ενωσεις οι οποιες εχουν δραστικοτητα ανταγωνιστη μουσκαρινικου υποδοχεα και αγωνιστη βητα2 αδρενεργικου υποδοχεα | |
| JP2021505620A5 (cg-RX-API-DMAC10.html) | ||
| EA201390917A1 (ru) | Дигетероарильные соединения в качестве ингибиторов vps34 | |
| JP2011136997A5 (cg-RX-API-DMAC10.html) | ||
| RU2017143580A (ru) | Улучшенные последовательности уриказы и способы лечения | |
| JP2014518641A5 (cg-RX-API-DMAC10.html) | ||
| JP2013503110A5 (cg-RX-API-DMAC10.html) | ||
| JP2016515123A5 (cg-RX-API-DMAC10.html) | ||
| MA34645B1 (fr) | Nouvelles formes cristallines | |
| NZ624708A (en) | Methods for treating hyperuricemia in patients with gout using halofenate or halofenic acid and a second urate-lowering agent | |
| JP2014532758A5 (cg-RX-API-DMAC10.html) | ||
| JP2013504313A5 (cg-RX-API-DMAC10.html) | ||
| PH12014502282A1 (en) | Method for treating hyperuricemia in patients with gout using halofenate or halofenic acid and an anti-inflammatory agent |